As of June 30, 2025, cash, cash equivalents and marketable securities totaled $166.2 million compared to cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025. The decrease in cash is related to funding ongoing operations. Cash is expected to support current clinical and operational activities into early 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- ABOS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Acumen Pharmaceuticals’ Promising Alzheimer’s Study: A Potential Game-Changer?
- Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug
- Strategic Buy Rating for Acumen Pharmaceuticals: Leveraging JCR Collaboration to Enhance Asset Delivery and Differentiation
- Acumen Pharmaceuticals Partners with JCR for Alzheimer’s Treatment